Health ❯ Healthcare ❯ Oncology

Melanoma

Advanced Melanoma BRAF V600 Mutation Treatment Options Diagnosis Neoadjuvant Therapy Chimeric Antigen Receptor T-Cells Tumor-Infiltrating Lymphocytes T-Cell Receptor T-Cells Lung Cancer Immunotherapy Resistance Immunotherapy Vaccines Adjuvant Therapy Immune Checkpoint Inhibitors Treatment Protocols

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

Next steps center on Phase 3 confirmation, with full data pending.

FDA Accepts Replimune’s Resubmitted RP1 Melanoma Filing, Sets April 2026 Decision

TIM‑3 Triplet Therapy Shows Promise in Immunotherapy‑Resistant Melanoma Models

FDA Rejects Replimune’s RP1 Melanoma Immunotherapy